On May 11, 2025, Incyte Corporation settled a dispute with Novartis, agreeing to pay $280 million in royalties related to JAKAFI and reducing future royalty rates by 50%. As of March 31, 2025, Incyte had $537.1 million in accrued royalties for this dispute, with a $242.2 million adjustment to be recorded in Q2 2025.